1. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61: S58-S68.
2.
The Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol 2022; 7: 396-415.
3.
Sayiner M, Koenig A, Henry L. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis 2016; 20: 205-214.
4.
Chalasani N, Younossi Z, Lavine JE. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357.
5.
Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78: 1966-1986.
6.
Halota W, Flisiak R, Boroń-Kaczmarska A, et al. Recommendations for the treatment of hepatitis C, Polish Group of HCV Experts -2015. Przegl Epidemiol 2015; 69: 515-521.
7.
Halota W, Flisiak R, Boroń-Kaczmarska A, et al. Recommendations for the treatment of hepatitis C issued by the Polish Group of HCV Experts – 2016. Clini Exp Hepatol 2016; 2: 27-33.
8.
Halota W, Flisiak R, Juszczyk J, et al. Recommendations for the treatment of hepatitis C in 2017. Clin Exp Hepatol 2017; 3: 47-55.
9.
Halota W, Flisiak R, Juszczyk J, et al. Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020. Clin Exp Hepatol 2020; 6: 163-169.
10.
Tomasiewicz K, Flisiak R, Jaroszewicz J, et al. Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023. Clin Exp Hepatol 2023; 9: 1-8.
11.
Pawlotsky J-M, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol 2020; 73: 1170-1218.
12.
Fernandez CJ, Alkhalifah M, Afsar H, et al. Metabolic dysfunction-associated fatty liver disease and chronic viral hepatitis: The interlink. Pathogens 2024; 13: 68.
13.
Rafiq N, Younossi ZM. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C. Expert Rev Gastroenterol Hepatol 2008; 2: 207-215.
14.
Siphepho PY, Liu YT, Shabangu CS, et al. The impact of steatosis on chronic hepatitis C progression and response to antiviral treatments. Biomedicines 2021; 9: 1491.
15.
Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol 2021; 27: 1006-1021.
16.
Sanyal AJ. Review article: non‐alcoholic fatty liver disease and hepatitis C – risk factors and clinical implications. Aliment Pharmacol Ther 2005; 22: 48-51.
17.
Adinolfi L, Rinaldi L, Guerrera B, et al. NAFLD and NASH in HCV infection: Prevalence and significance in hepatic and extrahepatic manifestations. Int J Mol Sci 2016; 17: 803.
18.
Lonardo A. Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen. World J Gastroenterol 2014; 20: 7089.
19.
Chang M-L. Metabolic alterations and hepatitis C: From bench to bedside. World J Gastroenterol 2016; 22: 1461.
20.
Jiang D, Chen C, Liu X, et al. Concurrence and impact of hepatic steatosis on chronic hepatitis B patients: a systematic review and meta-analysis. Ann Transl Med 2021; 9: 1718-1718.
21.
Adinolfi L. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364.
22.
Ramesh S, Sanyal AJ. Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis 2004; 24: 399-413.
23.
Gabriel A, Kukla M, Adamek B, et al. Steatosis influences hepatocytes proliferative potential in chronic hepatitis C patients. Pol J Pathol 2018; 69: 388-394.
24.
Stan IS, Biciuşcă V, Durand P, et al. Diagnostic and prognostic significance of hepatic steatosis in patients with chronic hepatitis C. Rom J Morphol Embryol 2021; 62: 765-775.
25.
Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-490.
26.
Negro F. Steatosis and insulin resistance in response to treatment of chronic hepatitis C. J Viral Hepat 2012; 19: 42-47.
27.
Kobayashi N, Iijima H, Tada T, et al. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Eur J Gastroenterol Hepatol 2018; 30: 546-551.